Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3530239 | 0.81 | KMT2A (0.56) | ARGAAMEN1KMT2AMAPT | |
| SCHEMBL4076521 | 0.74 | KMT2A (0.57) | ARGAAMEN1KMT2AMAPT | |
| SCHEMBL4078988 | 0.74 | GAA (0.55) | ARGAAMEN1KMT2AMAPT | |
| SCHEMBL4087479 | 0.73 | KMT2A (0.47) | ARGAAMEN1KMT2AMAPT | |
| SCHEMBL3170904 | 0.72 | KMT2A (0.52) | ARGAAMEN1KMT2AMAPT | |
| SCHEMBL4086306 | 0.71 | AR (0.55) | ARGAAMEN1KMT2AMAPT | |
| SCHEMBL4795202 | 0.71 | AR (0.54) | ARGAAMEN1KMT2AMAPT | |
| SCHEMBL3161083 | 0.70 | GAA (0.49) | ARGAAMEN1KMT2AMAPT | |
| SCHEMBL3526486 | 0.70 | GAA (0.49) | ARGAAMEN1KMT2AMAPT | |
| SCHEMBL4081973 | 0.68 | AR (0.51) | ARGAAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652018-B2 | Imidazolidin-2-one derivatives useful as PR modulators | WYETH LLC (US) | 2010-01-26 | — | — | US | claimed |
| US-20080045577-A1 | 4-[2-(3,5,5-Trimethyl-2-oxoimidazolidin-1-yl)-1,3-thiazol-4-yl]benzonitrile; 1-[4-(4-Bromophenyl)-1,3-thiazol-2-yl]-3-methylimidazolidin-2-one; contraception, fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas | WYETH (US) | 2008-02-21 | — | — | US | claimed |
| US-7652018-B2 | Imidazolidin-2-one derivatives useful as PR modulators | WYETH LLC (US) | 2010-01-26 | — | — | US | disclosed |
| US-7618990-B2 | 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy | WYETH (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2008021309-A1 | IMIDAZOLIDIN-2-ONE DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045577-A1 | 4-[2-(3,5,5-Trimethyl-2-oxoimidazolidin-1-yl)-1,3-thiazol-4-yl]benzonitrile; 1-[4-(4-Bromophenyl)-1,3-thiazol-2-yl]-3-methylimidazolidin-2-one; contraception, fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045577-A1 | 4-[2-(3,5,5-Trimethyl-2-oxoimidazolidin-1-yl)-1,3-thiazol-4-yl]benzonitrile; 1-[4-(4-Bromophenyl)-1,3-thiazol-2-yl]-3-methylimidazolidin-2-one; contraception, fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas | PKD1, SHBG, NPY4R | AR 85/4885GAA 4857/4885MEN1 30/4885 |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | MC2R, NPY1R, PRLHR | AR 47/4885GAA 4758/4885MEN1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.